PAREXEL - Albert Liou Discusses the Drug Development Landscape in Korea
Korea is becoming a global hub for many reasons. There is a good infrastructure, good regulatory system, and there also there are a lot of professionals with good talent in this country. Since 2000’s, the government has made great reforms to the regulatory systems. For instance, GCP, global GCP has been implemented in Korea. And the Korean government has separated R&D and NDA processing. That makes clinical trials much easier to get an approval. And also they implemented 60-days for R&D review period. All of this makes the regulatory systems friendlier for clinical research and also aligned with the global systems. And another thing, hospital and medical centers, have made a lot of improvement since 2000’s. The government has put in a lot of funding to improve the infrastructure and also train a lot of good investigators in this area. And as a result - this makes Korea become a very important clinical research hub in Asia.